Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donidalorsen in moderate to severe COVID-19
NCT04549922Phase 2Completed
- Sponsor
- HCor
- Start
- Oct 2020
- Primary completion
- Dec 2020
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of donidalorsen in coronavirus disease 2019 (COVID-19), sponsored by HCor. Started Oct 2020; status: completed.
02
Drugs
donidalorsen
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04549922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04549922.